Ann: First Patient Dosed in Phase 2 Stroke Trial of ARG-007, page-23

You are correct in they do need capital, and they themselves have stated it. The positive with these guys is that if you look back at their financials, they are extremely fiscally responsible. So a cap raise is going to happen at some stage soon, but this could be a CU6 type of situation, where the raise happens at $1+ and possibly be pro rata.

So investors don't be disappointed by a cap raise, I feel this company knows how to spend well. Very rare. This is up there with RAC, EMV in terms of companies who value the cash and not raise perpetually like most biotechs.